[go: up one dir, main page]

PE20142357A1 - Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico - Google Patents

Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico

Info

Publication number
PE20142357A1
PE20142357A1 PE2014001115A PE2014001115A PE20142357A1 PE 20142357 A1 PE20142357 A1 PE 20142357A1 PE 2014001115 A PE2014001115 A PE 2014001115A PE 2014001115 A PE2014001115 A PE 2014001115A PE 20142357 A1 PE20142357 A1 PE 20142357A1
Authority
PE
Peru
Prior art keywords
phenol
propyl
ethyl
methyl
antiepyleptic
Prior art date
Application number
PE2014001115A
Other languages
English (en)
Inventor
Petra Bloms-Funke
Klaus Schiene
Thomas Christoph
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40345058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142357(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20142357A1 publication Critical patent/PE20142357A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA COMBINACION FARMACEUTICA QUE COMPRENDE: a) (IR,2R)-3-(3-DIMETILAMINO-1-ETIL-2-METIL-PROPIL)FENOL Y b) UN ANTIEPILEPTICO TAL COMO LEVETIRACETAM, DONDE LA REALCION DE MEZCLA ENTRE LOS COMPONENTES a) Y b) ES 1:20 A 1:564
PE2014001115A 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico PE20142357A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08015625 2008-09-05

Publications (1)

Publication Number Publication Date
PE20142357A1 true PE20142357A1 (es) 2015-02-04

Family

ID=40345058

Family Applications (5)

Application Number Title Priority Date Filing Date
PE2014001117A PE20142372A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
PE2011000206A PE20110291A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
PE2014001115A PE20142357A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
PE2018003303A PE20190914A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
PE2014001116A PE20142371A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2014001117A PE20142372A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
PE2011000206A PE20110291A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2018003303A PE20190914A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
PE2014001116A PE20142371A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico

Country Status (28)

Country Link
US (1) US20100063148A1 (es)
EP (2) EP2735338B1 (es)
JP (4) JP5731387B2 (es)
KR (3) KR101641519B1 (es)
CN (2) CN105520924B (es)
AR (2) AR073361A1 (es)
AU (3) AU2009289776A1 (es)
BR (1) BRPI0920521A2 (es)
CA (1) CA2735857C (es)
CL (1) CL2011000317A1 (es)
CO (1) CO6382142A2 (es)
CY (2) CY1115751T1 (es)
DK (2) DK2735338T3 (es)
EC (1) ECSP11010869A (es)
ES (2) ES2513394T3 (es)
HR (2) HRP20140663T1 (es)
HU (1) HUE043278T2 (es)
IL (3) IL211135A (es)
LT (1) LT2735338T (es)
MX (1) MX2011002339A (es)
PE (5) PE20142372A1 (es)
PL (2) PL2735338T3 (es)
PT (2) PT2735338T (es)
RU (2) RU2571501C2 (es)
SI (2) SI2735338T1 (es)
TR (1) TR201904388T4 (es)
WO (1) WO2010025931A2 (es)
ZA (1) ZA201101449B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
PT2462990E (pt) * 2006-06-15 2014-04-02 Ucb Pharma Gmbh Composição farmacêutica com efeito anticonvulsivo sinergístico
PE20142372A1 (es) * 2008-09-05 2015-02-04 Gruenenthal Chemie Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
HUE026619T2 (en) * 2010-06-15 2016-06-28 Gruenenthal Gmbh Pharmaceutical combination for the treatment of pain
WO2012003968A1 (en) 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
RU2544552C2 (ru) 2010-07-30 2015-03-20 Торэй Индастриз, Инк. Терапевтическое средство или профилактическое средство для нейропатической боли
CA2828635C (en) * 2011-03-04 2020-01-14 Grunenthal Gmbh Parenteral administration of tapentadol
EP2753302B1 (en) * 2011-07-20 2018-11-28 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol
ES2663403T3 (es) * 2011-07-29 2018-04-12 Grünenthal GmbH Administración intratecal o epidural de 3-[(1S,2S)-3-(dimetilamino)-1-etil-2-metilpropil]fenol
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US9320725B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
EP2914243A1 (en) * 2012-11-01 2015-09-09 Torrent Pharmaceuticals Limited Pharmaceutical composition of tapentadol for parenteral administration
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
PT3393655T (pt) 2015-12-22 2021-02-23 Zogenix International Ltd Composições de fenfluramina e métodos de preparação das mesmas
ES3029536T3 (en) * 2016-08-24 2025-06-24 Zogenix International Ltd Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2020105005A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
ATE284223T1 (de) * 1999-08-20 2004-12-15 Ortho Mcneil Pharm Inc Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
EP1480639A1 (en) * 2002-02-22 2004-12-01 Warner-Lambert Company LLC Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
WO2007005716A2 (en) 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
ES2358763T3 (es) * 2006-04-28 2011-05-13 Grünenthal GmbH Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un nsaid.
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
ES2619329T3 (es) * 2007-11-23 2017-06-26 Grünenthal GmbH Composiciones de tapentadol
JP5291123B2 (ja) * 2008-01-25 2013-09-18 ゼノポート，インコーポレイティド （３ｓ）−アミノメチル−５−ヘキサン酸プロドラッグの結晶形態及びその使用
PE20142372A1 (es) * 2008-09-05 2015-02-04 Gruenenthal Chemie Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico

Also Published As

Publication number Publication date
HRP20190500T1 (hr) 2019-08-09
PL2331210T3 (pl) 2014-12-31
PL2735338T3 (pl) 2019-07-31
AR117613A2 (es) 2021-08-18
CY1121492T1 (el) 2020-05-29
CN105520924B (zh) 2019-04-09
KR101851120B1 (ko) 2018-04-23
LT2735338T (lt) 2019-04-10
SI2735338T1 (sl) 2019-04-30
CL2011000317A1 (es) 2011-06-17
MX2011002339A (es) 2011-04-04
DK2735338T3 (en) 2019-04-23
RU2011112444A (ru) 2012-10-10
DK2331210T3 (da) 2014-08-11
CY1115751T1 (el) 2017-01-25
CN105520924A (zh) 2016-04-27
HK1198145A1 (en) 2015-03-13
AU2018202879A1 (en) 2018-05-17
AU2016203053B2 (en) 2018-01-25
CN102159284A (zh) 2011-08-17
IL211135A (en) 2017-09-28
CA2735857C (en) 2019-05-28
CA2735857A1 (en) 2010-03-11
CN102159284B (zh) 2015-12-09
JP5731387B2 (ja) 2015-06-10
CO6382142A2 (es) 2012-02-15
SI2331210T1 (sl) 2014-10-30
EP2331210A2 (en) 2011-06-15
IL237391A0 (en) 2015-04-30
HK1159011A1 (en) 2012-07-27
AU2016203053A1 (en) 2016-06-02
US20100063148A1 (en) 2010-03-11
AU2009289776A1 (en) 2010-03-11
PE20142371A1 (es) 2015-02-04
KR101730924B1 (ko) 2017-04-27
AU2018202879B2 (en) 2020-03-12
ZA201101449B (en) 2011-10-26
EP2735338B1 (en) 2019-02-06
WO2010025931A2 (en) 2010-03-11
KR20160086981A (ko) 2016-07-20
RU2571501C2 (ru) 2015-12-20
TR201904388T4 (tr) 2019-05-21
RU2674150C1 (ru) 2018-12-05
IL237392A0 (en) 2015-04-30
JP2012501986A (ja) 2012-01-26
JP2015096530A (ja) 2015-05-21
WO2010025931A3 (en) 2010-06-17
HUE043278T2 (hu) 2019-08-28
KR20170048602A (ko) 2017-05-08
IL237391A (en) 2017-12-31
ECSP11010869A (es) 2011-04-29
JP2017071636A (ja) 2017-04-13
HRP20140663T1 (hr) 2014-10-10
EP2331210B1 (en) 2014-07-09
PE20190914A1 (es) 2019-06-26
ES2719900T3 (es) 2019-07-16
PE20110291A1 (es) 2011-06-04
PT2331210E (pt) 2014-08-25
EP2735338A1 (en) 2014-05-28
ES2513394T3 (es) 2014-10-27
PE20142372A1 (es) 2015-02-04
IL237392B (en) 2019-08-29
BRPI0920521A2 (pt) 2018-01-16
KR101641519B1 (ko) 2016-07-21
PT2735338T (pt) 2019-05-24
AR073361A1 (es) 2010-11-03
IL211135A0 (en) 2011-04-28
KR20110057144A (ko) 2011-05-31
JP2019131578A (ja) 2019-08-08

Similar Documents

Publication Publication Date Title
PE20142357A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
CL2008002076A1 (es) Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades.
CR9786A (es) Compuestos de bencimidazol-tiofeno
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
CL2012002945A1 (es) Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
CL2007003065A1 (es) Compuestos derivados de benzodioxano, agonista 5ht2c, composicion farmaceutica que lois comprende; y sus uso en el tratamiento de un trastorno psicotico, ansiedad, depresion, trastorno bipolar, sindrome premenstrual, entre otros
EA201300756A1 (ru) Композиции для осветления цвета кожи
UY30304A1 (es) Moduladores de mglur5 i
CL2011000603A1 (es) Uso de compuestos de ditiina-tetracarboximidas que sirven para combatir hongos fitopatogenos; procedimiento para combatir dichos hongos; compuestos de ditiina-tetracarboximidas; uso de compuestos de ditiina-diisoimidas; y compuestos ditiina-diisoimidas.
ECSP088854A (es) Moduladores bencimidazolicos de vr1
CL2009000404A1 (es) Compuestos derivados de piperidin-indol-sustituidos, moduladores de receptores nociceptina/orl1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades del snc, cardiovasculares, metabolicas, entre otras.
CL2007002970A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
CL2012002551A1 (es) Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
UY30308A1 (es) Moduladores de mglur5 v
UY30306A1 (es) Moduladores de mglur5 iii
UY30307A1 (es) Moduladores de mglur5 vi
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
CL2011002233A1 (es) Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico.
AR047759A1 (es) Derivados de fenil - piperazina como moduladores de receptores muscarnicos

Legal Events

Date Code Title Description
FG Grant, registration